Floatz logo

Ebselen

Ototoxicity

Sound Pharmaceuticals, IncorporatedSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Ototoxicity cohort.

Asset / SponsorPhaseRating
D-thioctic acid
US Department of Veterans Affairs
Phase 2/3B
Sodium Thiosulfate
Children's Oncology Group
Phase 3B
Spi-1005 Ebselen
Sound Pharmaceuticals, Incorporated
Phase 2B

Same molecule, other indications

Ebselen is also rated in:

manic bipolar affective disorderDormant
B
Indicative ·
57 / 100
View asset →
bipolar disorderDormant
CCC
Indicative ·
54 / 100
View asset →
depressive disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →